Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. EBT Margin for the year ending December 31, 2023: -68.36%

Biomm S.A. EBT Margin is -68.36% for the year ending December 31, 2023, a 23.01% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Biomm S.A. EBT Margin for the year ending December 31, 2022 was -88.79%, a -19.18% change year over year.
Biomm S.A. EBT Margin for the year ending December 31, 2021 was -74.50%, a 38.18% change year over year.
Biomm S.A. EBT Margin for the year ending December 31, 2020 was -120.52%, a 80.67% change year over year.
Biomm S.A. EBT Margin for the year ending December 31, 2019 was -623.59%, a 77.04% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years